Editas Medicine’s Post

Silo Pharma recently provided an update regarding the exercise of our option to license SPC-14, an Alzheimer's disease therapeutic candidate, from Columbia University. This action follows a sponsored research and option agreement established in 2021. Full details are available here: https://bit.ly/3UftyfC #Science #Biotech #Biotechnology #ADResearch

Earlier today, we shared a strategic update where we discussed progress towards our 2024 goals, including achievement of establishing in vivo preclinical proof of concept. Learn more: https://bit.ly/3YyS3GL #geneediting #biotechnology  

Our Head of Protein Sciences, Nicholas Marshall, will be presenting at the upcoming PepTalk meeting in San Diego. His talk will highlight how Invenra is using the B-Body Platform to accelerate the discovery of novel bispecific ADCs by enabling parallel screening of antibody combinations against multiple targets. #Invenra #AntibodyEngineering #Innovation #Biotech #BispecificADCs #AntibodyDrugConjugates

Discover how #microgravity research is unlocking new possibilities in #protein crystallization, driving breakthroughs in #drug discovery and advancing life sciences. https://lnkd.in/gHJdZDMF #drug #biotechnology #research #lifescience

Redefining drug development: In a recent webinar hosted by Contract Pharma, Rita Cruz, Ingenza Ltd’s Head of Molecular Biology, shared her insights into our innovative inGenius platform and its potential to transform #DrugDevelopment. This powerful tool is changing the way we approach complex molecular challenges, pushing boundaries like never before. Visit our website to watch the full webinar about how Ingenza is pioneering advancements! https://ow.ly/Eiz850UgKZv #InnovationInBiotech #MolecularBiology

Congratulations to Nuclera on securing $75 million in Series C financing! Nuclera, the Amadeus-backed biotechnology company revolutionising protein expression and purification workflows with its eProtein Discovery™ benchtop system, has successfully closed a $75 million financing round. This significant investment, led by Elevage Medical Technologies and supported by Patient Square Capital, British Patient Capital, and others, will accelerate the commercialization of Nuclera’s innovative platform. Dr. Michael Chen, CEO and co-founder of Nuclera, shared: “This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come.” Dr. Michael Wasserman, COO of Elevage Medical Technologies, added: “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process. Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe.” 🔗Read the full release here: https://bit.ly/48b0bQX #Nuclera #SeriesC #biotech #proteinexpression #drugdiscovery

Read full article: https://lnkd.in/gvAdUSWi Dive into the future of mRNA therapeutics with #ddPCR technology! Discover how this #technology offers ultra-sensitive detection and precision for quantifying mRNA and detecting rare contaminants. Read the article to see how ddPCR is transforming the field! #Research #Biotechnology #PrecisionMedicine

Read full article: https://lnkd.in/gvAdUSWi Dive into the future of mRNA therapeutics with #ddPCR technology! Discover how this #technology offers ultra-sensitive detection and precision for quantifying mRNA and detecting rare contaminants. Read the article to see how ddPCR is transforming the field! #Research #Biotechnology #PrecisionMedicine

Nyrada Inc. . reports promising results from NYR-BI03 studies, showing significant cardioprotective effects and paving the way for upcoming clinical trials. Read More https://lnkd.in/gSxk63jZ #NYRBI03, #cardioprotection, #ischemiaReperfusion, #clinicalTrial, #biotechnology

Functional personalized medicine is an interesting approach aiming at identifying unexpected therapeutic options for each patient. Patient-derived organoids appear as a promising and scalable technology to enable ex vivo drug tests and implement them in the clinics Read More: https://lnkd.in/eAYZd2fc #cellculture #researcher #kosheeka #biotechnology #primarycells